Journals
 
 
 
RSS feed based on search criteria Export search results - CSV (plain text) Export search results - XML
Add search criteria
2015-06-16 [p.2784]
Q-1276 — Ms. Moore (Abitibi—Témiscamingue) — With regard to contracts under $10 000 awarded by Health Canada since April 1, 2014: what is (i) the name of the supplier, (ii) the contract reference number, (iii) the contract date, (iv) the description of services provided, (v) the delivery date, (vi) the original contract amount, (vii) the final contract amount, if different from the original amount? — Sessional Paper No. 8555-412-1276.
2015-06-12 [p.2754]
Q-1249 — Mr. Lamoureux (Winnipeg North) — With regard to contracts under $10 000 granted by Health Canada since January 30, 2015: what are the (a) vendors' names; (b) contracts' reference numbers; (c) dates of the contracts; (d) descriptions of the services provided; (e) delivery dates; (f) original contracts' values; and (g) final contracts' values, if different from the original contracts' values? — Sessional Paper No. 8555-412-1249.
2015-06-01 [p.2600]
Q-1165 — Ms. Fry (Vancouver Centre) — With regard to Health Canada’s regulations on flavoured tobacco in cigarettes, cigars and cigarillos: (a) what percentage of the total number of consumers for each product are over the age of 18; (b) what percentage of the total number of consumers for each product are under the age of 18; (c) what percentage of each of these products contains menthol; (d) why did Health Canada exempt menthol flavoured cigarettes and cigarillos from the new regulations on flavoured tobacco; and (e) what organizations and individuals were consulted on the decision to exempt menthol cigarettes and cigarillos from the new regulations? — Sessional Paper No. 8555-412-1165.
2015-05-12 [p.2518]
Mr. Lobb (Huron—Bruce), from the Standing Committee on Health, presented the 11th Report of the Committee (Main Estimates 2015-16 — Votes 1 and 5 under CANADIAN FOOD INSPECTION AGENCY, Votes 1 and 5 under CANADIAN INSTITUTES OF HEALTH RESEARCH, Votes 1, 5 and 10 under HEALTH, Vote 1 under PATENTED MEDICINE PRICES REVIEW BOARD and Votes 1, 5 and 10 under PUBLIC HEALTH AGENCY OF CANADA). — Sessional Paper No. 8510-412-229.
A copy of the relevant Minutes of Proceedings (Meeting No. 61) was tabled.
2015-04-20 [p.2366]
Q-1063 — Ms. Bennett (St. Paul's) — With regard to Aboriginal Affairs and Northern Development Canada and to each First Nation reserve community: (a) does the community have its own on-reserve fire department or fire protective service; (b) if the answer to (a) is negative, does the community have a contract or agreement with a municipality or other fire department or fire protective service, providing (i) the name of the other party to that contract or agreement, (ii) the start and end dates of that contract or agreement; (c) if the answer to (b) is negative, did the community formerly have a contract or agreement with a municipality or other fire department or fire protective service, providing (i) the name of the other party to that contract or agreement, (ii) the start and end dates of that contract or agreement, (iii) the reason for which the contract or agreement is no longer in force; and (d) what are the titles, dates, and file numbers of all reports, briefing materials, briefing notes, memoranda, dossiers, dockets, or assessments, created or modified since January 1, 2010, held by Aboriginal Affairs and Northern Development Canada, Public Safety Canada, Health Canada, the Royal Canadian Mounted Police, or Intergovernmental Affairs, concerning fire protective services in any particular First Nations reserve community or group of communities, or concerning fire protective services in First Nations reserve communities in general? — Sessional Paper No. 8555-412-1063.
2015-04-20 [p.2368]
Q-1072 — Mr. Scarpaleggia (Lac-Saint-Louis) — With regard to Health Canada's Food Labelling Modernization Initiative of Proposed Daily Values (DV) for sugars and trans fats: (a) how did Health Canada determine a DV of 100 grams of sugar; (b) with which individuals or agencies did Health Canada consult to arrive at a proposed DV of 100 grams of sugar; (c) during consultations, did any individuals or agencies propose a lower DV than 100 grams and, if so, (i) which individuals or agencies did so, (ii) what reasons were given for disregarding their suggestions of a DV of sugar lower than 100 grams; (d) which peer-reviewed, independent, scientific research articles were referenced to support the proposed DV of 100 grams of sugar; (e) during consultations, which peer-reviewed, independent, scientific research articles were referenced that supported a DV lower than 100 grams, and what reasons were given for disregarding their conclusions; (f) why was the World Health Organization's recommended DV of 25 grams of sugar not adopted; (g) how did Health Canada determine a DV of 2 grams of trans fats; (h) with which individuals or agencies did Health Canada consult to arrive at a proposed DV of 2 grams of trans fats; (i) during consultations, did any individuals or agencies propose a lower DV than 2 grams of trans fats and, if so, (i) which individuals or agencies did so, (ii) what reasons were given for disregarding their suggestions of a DV of trans fats lower than 2 grams; (j) which peer-reviewed, independent, scientific research articles were referenced to support the proposed DV of 2 grams of trans fats; (k) during consultations, which peer-reviewed, independent, scientific research articles were referenced that supported a DV of trans fats lower than 2 grams and what reasons were given for disregarding their conclusion; and (l) why were the World Health Organization's statements that "industrial trans fats [...] do not belong in a healthy diet" and that fat consumption should shift "towards the elimination of industrial trans fats" not interpreted to mean a DV of 0 grams? — Sessional Paper No. 8555-412-1072.
2015-03-31 [p.2324]
Pursuant to Standing Order 32(2), Mr. Clement (President of the Treasury Board) laid upon the Table, — Reports on Plans and Priorities, Main Estimates, 2015-16 (USB key included), as follows:
(1) Aboriginal Affairs and Northern Development Canada and Canadian Polar Commission. - Sessional Paper No. 8520-412-99;
(2) Administrative Tribunals Support Service of Canada. - Sessional Paper No. 8520-412-100;
(3) Agriculture and Agri-Food Canada. - Sessional Paper No. 8520-412-101;
(4) Atlantic Canada Opportunities Agency. - Sessional Paper No. 8520-412-102;
(5) Canada Border Services Agency. - Sessional Paper No. 8520-412-103;
(6) Canada Economic Development for Quebec Regions. - Sessional Paper No. 8520-412-104;
(7) Canada Revenue Agency. - Sessional Paper No. 8520-412-105;
(8) Canada School of Public Service. - Sessional Paper No. 8520-412-106;
(9) Canadian Centre for Occupational Health and Safety. - Sessional Paper No. 8520-412-107;
(10) Canadian Environmental Assessment Agency. - Sessional Paper No. 8520-412-108;
(11) Canadian Food Inspection Agency. - Sessional Paper No. 8520-412-109;
(12) Canadian Grain Commission. - Sessional Paper No. 8520-412-110;
(13) Canadian Heritage. - Sessional Paper No. 8520-412-111;
(14) Canadian Human Rights Commission. - Sessional Paper No. 8520-412-112;
(15) Canadian Institutes of Health Research. - Sessional Paper No. 8520-412-113;
(16) Canadian Intergovernmental Conference Secretariat. - Sessional Paper No. 8520-412-114;
(17) Canadian Northern Economic Development Agency. - Sessional Paper No. 8520-412-115;
(18) Canadian Nuclear Safety Commission. - Sessional Paper No. 8520-412-116;
(19) Canadian Radio-television and Telecommunications Commission. - Sessional Paper No. 8520-412-117;
(20) Canadian Space Agency. - Sessional Paper No. 8520-412-118;
(21) Canadian Transportation Agency. - Sessional Paper No. 8520-412-119;
(22) Citizenship and Immigration Canada. - Sessional Paper No. 8520-412-120;
(23) Civilian Review and Complaints Commission for the RCMP. - Sessional Paper No. 8520-412-121;
(24) Copyright Board of Canada. - Sessional Paper No. 8520-412-122;
(25) Correctional Service of Canada. - Sessional Paper No. 8520-412-123;
(26) Courts Administration Service. - Sessional Paper No. 8520-412-124;
(27) Department of Finance Canada. - Sessional Paper No. 8520-412-125;
(28) Department of Justice Canada. - Sessional Paper No. 8520-412-126;
(29) Department of National Defence and the Canadian Armed Forces. - Sessional Paper No. 8520-412-127;
(30) Employment and Social Development Canada. - Sessional Paper No. 8520-412-128;
(31) Environment Canada. - Sessional Paper No. 8520-412-129;
(32) Federal Economic Development Agency for Southern Ontario. - Sessional Paper No. 8520-412-130;
(33) Financial Transactions and Reports Analysis Centre of Canada. - Sessional Paper No. 8520-412-131;
(34) Fisheries and Oceans Canada. - Sessional Paper No. 8520-412-132;
(35) Foreign Affairs, Trade and Development Canada. - Sessional Paper No. 8520-412-133;
(36) Health Canada. - Sessional Paper No. 8520-412-134;
(37) Immigration and Refugee Board of Canada. - Sessional Paper No. 8520-412-135;
(38) Industry Canada. - Sessional Paper No. 8520-412-136;
(39) Infrastructure Canada. - Sessional Paper No. 8520-412-137;
(40) Library and Archives Canada. - Sessional Paper No. 8520-412-138;
(41) Military Grievances External Review Committee. - Sessional Paper No. 8520-412-139;
(42) Military Police Complaints Commission of Canada. - Sessional Paper No. 8520-412-140;
(43) National Energy Board. - Sessional Paper No. 8520-412-141;
(44) National Film Board of Canada. - Sessional Paper No. 8520-412-142;
(45) National Research Council Canada. - Sessional Paper No. 8520-412-143;
(46) Natural Resources Canada. - Sessional Paper No. 8520-412-144;
(47) Natural Sciences and Engineering Research Council. - Sessional Paper No. 8520-412-145;
(48) Northern Pipeline Agency. - Sessional Paper No. 8520-412-146;
(49) Office of the Auditor General of Canada. - Sessional Paper No. 8520-412-147;
(50) Office of the Chief Electoral Officer. - Sessional Paper No. 8520-412-148;
(51) Office of the Commissioner for Federal Judicial Affairs Canada. - Sessional Paper No. 8520-412-149;
(52) Office of the Commissioner of Lobbying of Canada. - Sessional Paper No. 8520-412-150;
(53) Office of the Commissioner of Official Languages. - Sessional Paper No. 8520-412-151;
(54) Office of the Communications Security Establishment Commissioner. - Sessional Paper No. 8520-412-152;
(55) Office of the Correctional Investigator. - Sessional Paper No. 8520-412-153;
(56) Office of the Information Commissioner of Canada. - Sessional Paper No. 8520-412-154;
(57) Office of the Privacy Commissioner of Canada. - Sessional Paper No. 8520-412-155;
(58) Office of the Public Sector Integrity Commissioner of Canada. - Sessional Paper No. 8520-412-156;
(59) Office of the Superintendent of Financial Institutions. - Sessional Paper No. 8520-412-157;
(60) Parks Canada Agency. - Sessional Paper No. 8520-412-158;
(61) Parole Board of Canada. - Sessional Paper No. 8520-412-159;
(62) Patented Medicine Prices Review Board. - Sessional Paper No. 8520-412-160;
(63) Privy Council Office. - Sessional Paper No. 8520-412-161;
(64) Public Health Agency of Canada. - Sessional Paper No. 8520-412-162;
(65) Public Prosecution Service of Canada. - Sessional Paper No. 8520-412-163;
(66) Public Safety Canada. - Sessional Paper No. 8520-412-164;
(67) Public Service Commission of Canada. - Sessional Paper No. 8520-412-165;
(68) Public Works and Government Services Canada. - Sessional Paper No. 8520-412-166;
(69) RCMP External Review Committee. - Sessional Paper No. 8520-412-167;
(70) Royal Canadian Mounted Police. - Sessional Paper No. 8520-412-168;
(71) Security Intelligence Review Committee. - Sessional Paper No. 8520-412-169;
(72) Shared Services Canada. - Sessional Paper No. 8520-412-170;
(73) Social Sciences and Humanities Research Council. - Sessional Paper No. 8520-412-171;
(74) Statistics Canada. - Sessional Paper No. 8520-412-172;
(75) Status of Women Canada. - Sessional Paper No. 8520-412-173;
(76) Supreme Court of Canada. - Sessional Paper No. 8520-412-174;
(77) The National Battlefields Commission. - Sessional Paper No. 8520-412-175;
(78) Transport Canada. - Sessional Paper No. 8520-412-176;
(79) Transportation Safety Board of Canada. - Sessional Paper No. 8520-412-177;
(80) Treasury Board of Canada Secretariat. - Sessional Paper No. 8520-412-178;
(81) Veterans Affairs Canada. - Sessional Paper No. 8520-411-179;
(82) Veterans Review and Appeal Board. - Sessional Paper No. 8520-412-180;
(83) Western Economic Diversification Canada. - Sessional Paper No. 8520-412-181.
8520-412-100 Main Estimates, 2015-2016 ...8520-412-101 Main Estimates, 2015-2016 ...8520-412-102 Main Estimates, 2015-2016 ...8520-412-103 Main Estimates, 2015-2016 ...8520-412-104 Main Estimates, 2015-2016 ...8520-412-105 Main Estimates, 2015-2016 ...8520-412-106 Main Estimates, 2015-2016 ...8520-412-107 Main Estimates, 2015-2016 ...8520-412-108 Main Estimates, 2015-2016 ...8520-412-109 Main Estimates, 2015-2016 ...8520-412-110 Main Estimates, 2015-2016 ...
...Show all topics
2015-03-20 [p.2255]
Q-970 — Ms. Fry (Vancouver Centre) — With regard to contracts under $10 000 granted by Health Canada since March 28, 2014: what are the (a) vendors' names; (b) contracts' reference numbers; (c) dates of the contracts; (d) descriptions of the services provided; (e) delivery dates; (f) original contracts' values; and (g) final contracts' values, if different from the original contracts' values? — Sessional Paper No. 8555-412-970.
2015-03-20 [p.2261]
Q-1020 — Mr. Rankin (Victoria) — With regard to Health Canada and the regulation of pharmaceutical manufacturing companies for the last ten years: (a) how many companies inspected in Canada have received a “proposal to suspend” letter, broken down by year; (b) how many companies inspected in Canada have received an “immediate suspension,” broken down by year; (c) how many companies inspected in Canada that were not sent a “proposal to suspend” letter or subject to a suspension has Health Canada worked with following an inspection to bring about compliance, broken down by year; (d) how many companies inspected in Canada have been subject to a re-inspection within six months, broken down by year; (e) how many companies inspected internationally have received a “proposal to suspend” letter, broken down by year; (f) how many companies inspected internationally have received an “immediate suspension,” broken down by year; (g) how many companies inspected internationally that were not sent a proposal to suspend letter or subject to a suspension has Health Canada worked with following an inspection to bring about compliance, broken down by year; (h) how many pharmaceutical manufacturing companies inspected internationally have been subject to a re-inspection within six months, broken down by year; (i) how many Import Alerts has Health Canada issued with regard to non-compliant health products, broken down by year; (j) which companies have been subject to an Import Alert; (k) how many voluntary quarantine requests has Health Canada issued, broken down by year; (l) which companies have been subject to a voluntary quarantine request; (m) how many “Notice of Intent to Suspend” letters have been issued to clinical trials, broken down by year; (n) how many “immediate suspensions” has Health Canada issued to clinical trials, broken down by year; (o) how many complaints have been received regarding off-label prescriptions of drugs, broken down by year; and (p) how many cases has Health Canada referred to the Public Prosecution Service of Canada for off-label prescriptions of drugs? — Sessional Paper No. 8555-412-1020.
2015-03-12 [p.2232]
Q-939 — Mr. Morin (Chicoutimi—Le Fjord) — With regard to the Health Canada decision not to certify citronella-based insect repellents: (a) what studies comparing the toxicity of insect repellents containing DEET with repellents containing citronella does Health Canada have at its disposal, and what are the findings of these studies; (b) during its citronella safety assessment, what groups did Health Canada consult to obtain scientific opinions; (c) did Health Canada receive solicited or unsolicited opinions, studies or documents from groups or scientists about the safety or toxicity of citronella used in insect repellent products and, if so, (i) from what groups or scientists did it receive them, (ii) on what date were these documents received, (iii) what were the findings of these documents; and (d) has Health Canada considered, or does it intend to consider, the possibility of creating a new category of products that would distinguish between chemical-based insect repellents and natural insect repellents, thereby allowing for the development of a separate safety certification process for natural products? — Sessional Paper No. 8555-412-939.
2015-02-20 [p.2157]
— by Ms. Ambrose (Minister of Health) — Report on the administration and operation of the Canada Health Act for the fiscal year ended March 31, 2014, pursuant to the Canada Health Act, R.S. 1985, c. C-6, s. 23. — Sessional Paper No. 8560-412-458-02. (Pursuant to Standing Order 32(5), permanently referred to the Standing Committee on Health)
2015-01-26 [p.1993]
Q-828 — Mr. Regan (Halifax West) — With respect to Health Canada’s marketing campaign concerning marijuana and prescription drugs, launched on or about October 20, 2014: (a) what are the names, positions, organizations or affiliations of all the stakeholders consulted leading up to this decision; (b) what submissions, proposals or recommendations were made by stakeholders during the consultation process; (c) what are the dates, times, and locations of the meetings with those individuals or organizations consulted; (d) how much funding has been allocated to the deployment of this proposal for fiscal year 2014-2015; (e) what are the next steps in this marketing campaign; (f) how is the effectiveness, reach, and impact of this campaign measured; and (g) what other methods is the Department or government considering to make Canadians more aware of the real dangers of drug abuse? — Sessional Paper No. 8555-412-828.
2015-01-26 [p.2010]
Q-888 — Ms. Davies (Vancouver East) — With regard to Health Canada: for the last ten years, (a) how many drug safety inspectors has Health Canada employed, broken down by year; (b) how many inspections of pharmaceutical manufacturing companies has Health Canada conducted within Canada, broken down by year; (c) how many pharmaceutical manufacturing companies inspected within Canada have received a warning letter or citation from Health Canada, broken down by year; (d) how many pharmaceutical manufacturing companies inspected within Canada have had penalties imposed, broken down by year; (e) how many pharmaceutical manufacturing companies inspected within Canada have been subject to a ban, broken down by year; (f) how many inspections of pharmaceutical manufacturing companies has Health Canada conducted internationally, broken down by year; (g) how many pharmaceutical manufacturing companies inspected internationally have received a warning letter or citation from Health Canada, broken down by year; (h) how many pharmaceutical manufacturing companies inspected internationally have had penalties imposed, broken down by year; (i) how many pharmaceutical manufacturing companies inspected internationally have been subject to a ban, broken down by year; (j) how many notices of violation concerning companies operating in Canada has Health Canada received from foreign regulators, broken down by year; (k) how many pharmaceutical manufacturing companies has Health Canada inspected because of a notification received from a foreign regulator, broken down by year; (l) how many clinical trials has Health Canada inspected, broken down by year; (m) how many clinical trials received a warning letter or citation from Health Canada following an inspection, broken down by year; (n) how many clinical trials have been shut down by Health Canada following an inspection, broken down by year; (o) how many investigations has Health Canada conducted regarding promotion of off-label prescription of drugs by pharmaceutical companies, broken down by year; (p) how many fines or penalties has Health Canada levied for off-label promotions, broken down by year; (q) how many reports of side effects relating to off-label prescriptions of pharmaceuticals has Health Canada received, broken down by year; and (r) when will Health Canada begin including side effects related to off-label prescriptions in its public database? — Sessional Paper No. 8555-412-888.
2015-01-26 [p.2018]
Q-910 — Ms. Davies (Vancouver East) — With regard to Health Canada: for the last ten years, broken down by year, (a) how many complaints have been received regarding pharmaceutical advertising targeted to consumers; (b) how many penalties or fines have been imposed for violations of the regulations regarding pharmaceutical advertising targeted to consumers; (c) how many warning letters or citations have been issued for violations of the regulations regarding pharmaceutical advertising targeted to consumers; and (d) which companies have been found to have violated the regulations regarding pharmaceutical advertising targeted to consumers? — Sessional Paper No. 8555-412-910.
2014-11-25 [p.1833]
Mr. Lobb (Huron—Bruce), from the Standing Committee on Health, presented the Seventh Report of the Committee (Supplementary Estimates (B), 2014-15 — Votes 1b and 5b under CANADIAN FOOD INSPECTION AGENCY, Vote 5b under CANADIAN INSTITUTES OF HEALTH RESEARCH, Votes 1b, 5b and 10b under HEALTH and Votes 1b, 5b and 10b under PUBLIC HEALTH AGENCY OF CANADA). — Sessional Paper No. 8510-412-146.
A copy of the relevant Minutes of Proceedings (Meeting No. 42) was tabled.
Results: 1 - 15 of 28 | Page: 1 of 2

1
2
>
>|